SIRPA and neoplasm: In addition to inhibiting binding between CD47 and SIRPα, antibodies targeting CD47 have the potential added benefit of blocking tumor-promoting cell-intrinsic CD47 signaling, but at the cost of challenges associated with the CD47 antigen sink.